-
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
•
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first half of 2024, reporting a 32.2% year-on-year (YOY) increase in revenues to RMB 1.383 billion, which includes a USD 90 million cooperation payment from its U.S. partner Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK),.…
-
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has reported a decline in its financial performance for the first half of 2024. The company’s overall revenues have dropped by 42.2% year-on-year to RMB 168 million (USD 23.7 million), with profits…
-
MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1
•
SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report for the first half of 2024, showing a revenue increase of 44.24% year-on-year to RMB 60.7382 million. Despite an expanded net loss of RMB 201 million, the company has significantly increased its research and development…
-
Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge
•
SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for the first half of 2024, reporting a 17.37% year-on-year increase in revenue to RMB 786 million. The net loss attributable to shareholders narrowed by RMB 352 million compared to the same period last year, reaching…
-
MicroPort Medical Reports 17% Revenue Growth in 2024H1, Driven by Subsidiaries’ Performance
•
HONG KONG—MicroPort Medical Science and Technology Co., Ltd (HKG: 0853), a leading medical device company, has released its financial report for the first half of 2024, showing a revenue increase of 17.0% year-on-year to $559 million, excluding the impact of currency exchange rates. The company’s loss for the period was…
-
Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024
•
Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its financial report for the first half of 2024, showcasing a revenue of RMB 204 million. This substantial growth is attributed to the rapid adoption of sunvozertinib, a cutting-edge epidermal growth factor receptor (EGFR) inhibitor, which…
-
Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1
•
SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first half of 2024, with revenues reaching RMB 20.53 billion, marking an 11.12% year-on-year increase. The net profit saw a robust rise, climbing to RMB 7.56 billion, which is a 17.37% increase. Despite a 7.59% YOY…
-
Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight
•
HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for the first half of 2024, reflecting a 46.0% year-on-year increase in revenues, which reached RMB 102.7 million. This growth is primarily attributed to the strong performance of its flagship hypoglycemic agent, HuaTangNing (dorzagliatin tablets). Despite…
-
Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs
•
Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1801), has announced its interim results for 2024 along with significant business updates. The company reported a robust year-over-year (YOY) growth in total revenue, which stood at RMB 3,952.3 million, marking…
-
Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues
•
Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported its financial results for the first half of 2024. The company recorded revenues of RMB 3.0746 billion, marking a 6% increase year-on-year (YOY), and a significant surge in net profits, which rose by 201% YOY…
-
Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report
•
Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176), has reported a staggering year-on-year (YOY) increase of 103,397.96% in its 2024H1 financial report, with revenues reaching RMB 80.4934 million. The second quarter of the year saw even more impressive growth, achieving RMB 56.1739 million,…
-
Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments
•
Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first half of 2024. The company recorded a modest year-on-year (YOY) increase in revenue, reaching RMB 1.323 billion, which is a 2.5% uptick. More impressively, the adjusted net profit saw a substantial surge of 395.0% YOY,…
-
Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency
•
Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952), has reported its financial results for the first half of 2024. The firm’s revenues experienced a substantial month-on-month increase of 158%, reaching RMB 302 million for the six-month period, primarily propelled by sales of the…
-
Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and the Hong Kong Stock Exchange (HKG: 2196), has reported its financial results for the first half of 2024. The Chinese pharmaceutical giant recorded an operating revenue of RMB 20.463 billion, reflecting a 5.31% year-on-year increase,…
-
Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability
•
Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced its 2024H1 financial report through its controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955). The report reveals a significant year-on-year (YOY) increase in total revenues, which stood at RMB 363 million, a rise of…
-
Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition
•
Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the…
-
BeiGene Positions for Global Growth with Strong Half-Year Results and R&D Investment
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) reported robust second-quarter 2024 results, highlighting significant corporate advancements that position the company for future global expansion. For the first half of 2024, BeiGene achieved total operating revenue of USD 1.6808 billion, reflecting a 61.1% year-on-year (YOY) increase. Product revenue surged by 73.0%…
-
Shanghai Henlius Biotech Reports 9.8% YOY Revenue Growth and Continued Profitability in 2024H1 Financial Report
•
Shanghai Henlius Biotech Inc., a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 2696), has reported its financial results for the first half of 2024, with a 9.8% year-on-year (YOY) increase in revenue, amounting to RMB 2.7461 billion. The company has sustained profitability, building…
-
MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported its financial results for the first half of 2024, demonstrating robust growth. The company’s revenue reached RMB 787 million, marking a 26.63% increase year-on-year (YOY). The operating profit soared to RMB 472 million, a 44.46%…
-
Shanghai Pharmaceuticals Posts 5.14% YOY Revenue Growth in 2024H1 with Focus on Cell Therapies
•
Shanghai Pharmaceuticals Holding Co. (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the first half of 2024, reporting a 5.14% year-on-year (YOY) increase in revenues, which reached RMB 139.413 billion. The pharmaceutical industry sector saw a decline in revenue, with a 13.37% YOY decrease to RMB 12.734…
